INTRACARDIAC CLOTS: IS RIVAROXABAN THE FUTURE?

Afrasayab Altaf, Momin Salahuddin, Momin Khan, Mazhar Mahmood, Karamat Ali Shah

Abstract


Intracardiac clots, including Left atrial (LA) clots and Left ventricular (LV) clots can be potentially life threatening for the patient and challenging for the physician. The traditionally used Vitamin-K antagonists although to a certain extent effective in treatment, do have some disadvantages that limit their use. New treatment options have to be explored to ensure more effective and efficient therapy.

The advent of new oral anticoagulants (NOACs), which are currently not approved for treatment of intracardiac clots, might add to the armory against them. One such NOAC, Rivaroxaban is the first to be approved for treatment of DVT and PE, and for the secondary prevention of VTE. Here, we review the cases reported and the possible use of Rivaroxaban for treatment of intra cardiac clots.

Keywords: Anticoagulants; Rivaroxaban; Thrombosis; Thrombin; Prothrombin; Hemostasis; Platelet Activation; Vitamin K.


Full Text:

XML PDF

References


Ahrens I, Bode C. Clinical utility of Rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation- patient considerations. J Blood Med. 2014 Feb;5:25-30.

Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost. 2010 Jul;104(1):49-60.

Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T, Iwamoto M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost. 1994 Mar;71(3):314-19.

Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of Rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. 2011 Jan;10(1):61-75.

Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. Circulation. 2003 April 1;107(12):1692–1711.

Prins MH, Lensing AWA, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, et al. Oral Rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal. 2013 Sep;11(1):21-9.

Prandoni P, Lensing AW, Buller HR, Carta M, Cogo A, Vigo M, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992 Feb 22;339(8791):441-5.

The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997 Sep 4;337(10):657-62.

Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H; the RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009 Dec 10; 361(24):2342-52.

Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):709-18.

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):699-708.

The EINSTEIN Investigators. Oral Rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010 Dec 23;363(26):2499-2510.

The EINSTEIN-PE Investigators. Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 Apr 5;366(14):1287-97.

Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb 14;141(2 Suppl):e419S-e494S.

Hokusai-VTE Investigators; Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10;369(15):1406-15.

Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014 Feb 18;129(7):764-72.

Paikin JS, Manolakos JJ, Eikelboom JW. Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial. Expert Rev Cardiovasc Ther. 2012 Aug;10(8):965-72.

Billingsley IM, Leong-poi H. Left ventricular thrombus: diagnosis, prevention and management. Cardiology Rounds. 2005;10(7):1-6.

Asinger RW, Mikell FL, Elsperger J, Hodges M. Incidence of left-ventricular thrombosis after acute transmural myocardial infarction. Serial evaluation by two-dimensional echocardiography. N Engl J Med. 1981 Aug 6;305(6):297-302.

Ciaccheri M, Castelli G, Cecchi F, Nannini M, Santoro G, Troiani V, et al. Lack of correlation between intracavitary thrombosis detected by cross sectional echocardiography and systemic emboli in patients with dilated cardiomyopathy. Br Heart J. 1989 Jul;62(1):26-9.

Gottdiener JS, Gay JA, VanVoorhees L, DiBianco R, Fletcher RD. Frequency and embolic potential of left ventricular thrombus in dilated cardiomyopathy: assessment by 2-dimensional echocardiography. Am J Cardiol. 1983 Dec 1;52(10):1281-5.

Delewi R, Zijlstra F, Piek JJ. Left ventricular thrombus formation after acute myocardial infarction. Heart. 2012 Dec;98(23):1743-9.

Moutzouris JP, Ng AC, Chow V, Chung T, Curnow J, Kritharides L. Acute pulmonary embolism during warfarin therapy and long- term risk of recurrent fatal pulmonary embolism. Thromb Haemost. 2013 Sep;110(3):523-33.

Gallus AS, Baker RI, Chong BH, Ockelford PA, Street AM. Consensus guidelines for warfarin therapy. Recommendations from the Australasian Society of Thrombosis and Haemostasis. Med J Aust. 2000 Jun 19;172(12): 600-5.

Morris L, Stevermer JJ. PURLs: An alternative to warfarin for patients with PE (Comment). J Fam Pract. 2012 Dec 6;61(12):751-2.

Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, et al. Ximelagatran vs low-molecular weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA. 2005 Feb 9;293(6):681-9.

Jamal N, Bapumia M. Dual antiplatelet agents and Rivaroxaban for massive intracoronary thrombus in STEMI. Clinical Case Reports. 2015 Nov;3(11):927-31.

American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. J Am Coll Cardiol. 2013 Jan 29;61(4):485-510.

Sianos G, Papafaklis MI, Serruys PW. Angiographic thrombus burden classification in patients with ST- segment elevation myocardial infarction treated with percutaneous coronary intervention. J Invasive Cardiol. 2010 Oct;22(10 Suppl B):6B-14B.

Jacobsen A. Is there a role for warfarin anymore? Hematology Am Soc Hematol Educ Program. 2012;2012:541-6.

Nakasuka K, Ito S, Noda T, Hasuo T, Sekimoto S, Ohmori H, et al. Resolution of left ventricular thrombus secondary to tachycardia-induced heart failure with Rivaroxaban. Case Rep Med. 2014;2014:814524.

Padilla Pérez M, Salas Bravo D, Garcelán Trigo JA, Vazquez Ruiz de Castroviejo E, Torres Llergo J, Lozano Cabezas C, et al. Resolution of left ventricular thrombus by Rivaroxaban. Future Cardiol. 2014 May;10(3):333-6.

Yeh CH, Fredenburgh JC, Weitz JI. Oral direct factor Xa inhibitors. Circulation Research. 2012 Sep 28;111(8):1069-78.

Flierl U, Fraccarollo D, Micka J, Bauersachs J, Schäfer A. The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure. Pharmacological Research. 2013 Aug;74:49-55.

Marino B, Kim J, Spinelli M. Persistent Left Atrial Appendage Thrombus with Use of Rivaroxaban. Eplabdigest.com [Webpage] 2015 Mar;15(3). Available from: https://www.eplabdigest.com/articles/Persistent-Left-Atrial-Appendage-Thrombus-Use-Rivaroxaban.

Lip GY, Hammerstingl C, Marin F, Cappato R, Meng IL, Kirsch B, et al. Rationale and design of a study exploring the efficacy of once-daily oral Rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2015 Apr;169(4):464-71.

Corrado G, Tadeo G, Beretta S, Tagliagambe LM, Manzillo GF, Spata M, et al. Atrial thrombi resolution after prolonged anticoagulation in patients with atrial fibrillation. Chest. 1999 Jan;115(1):140-3.

Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011 Jan 18;123(2):131-6.

The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med. 1998 Apr 15:128(8):639-47.

De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al. General mechanisms of coagulation and targets of anticoagulants (section I). Position paper of the ESC Working Group on Thrombosis–Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013 Apr;109(4):569-79.

Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012 Nov;33(21):2719-47.

Hammerstingl C, Pötzsch B, Nickenig G. Resolution of giant left atrial appendage thrombus with Rivaroxaban. Thromb Haemost. 2013 Apr;109(4):583-4.

Takasugi J, Yamagami H, Okata T, Toyoda K, Ngatsuka K. Dissolution of the left atrial appendage thrombus with Rivaroxaban therapy. Cerebrovasc Dis. 2013 Oct;36(4):322-3.

Müller I, Besta F, Schulz C, Massberg S, Schönig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003 May;89(5):783-7.

Gori AM, Marcucci R, Migliorini A, Valenti R, Moschi G, Paniccia R, et al. Incidence and clinical impact of dual nonresponsiveness to Aspirin and Clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol. 2008 Aug;52(9):734-9.

American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions, O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Jan 29;61(4):e78-140.

Nakasuka K, Noda SIT, Hasuo T, Sekimoto S, Ohmori H, Inomata M, et al. Resolution of left ventricular thrombus secondary to tachycardia-induced heart failure with Rivaroxaban. Case Rep Med. 2014;2014:814524.

Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL


Refbacks

  • There are currently no refbacks.